FDA Approved: MEKINIST — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

The FDA approved a supplemental application for MEKINIST (trametinib) from Novartis Pharmaceuticals Corporation. This action updates the drug's labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Non-small Cell Lung Cancer

Drugs mentioned

• MEKINIST (trametinib)

Snippet

SUPPL AP for MEKINIST (TRAMETINIB)